VivoSeq
Oncology

Hematologic Cancer

2

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Hematologic Cancer is an early-stage landscape with 2 programs across 9 companies. The most active players are AbbVie, Bristol-Myers Squibb, Vion Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

75/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

2 programs

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalV

Vion Pharmaceuticals

0 programs

PreclinicalJazz Pharmaceuticals logo

Jazz Pharmaceuticals

0 programs

PreclinicalC

Celldex Therapeutics

0 programs

PreclinicalS

Surface Oncology

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

ABBV-101

AbbVie

Venetoclax

AbbVie

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

55

clinical trials

Completed39 · 71%
Terminated11 · 20%
Withdrawn2 · 4%
Unknown status1 · 2%
Recruiting1 · 2%
Active, not recruiting1 · 2%

Clinical Trials

Trial Activity

55 trials

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Recruiting·IIndapta Therapeutics, INC.·Phase 1/2·NCT06119685·128 enrolled
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies
Active, not recruiting·AbbVie logoAbbVie·Phase 1·NCT05753501·135 enrolled
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Completed·VVion Pharmaceuticals·Phase 1·NCT00064090
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00031980·30 enrolled
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003805·859 enrolled
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00015951
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT02367196·60 enrolled
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT00290641·68 enrolled
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Completed·IIndiana University School of Medicine·Phase 1·NCT00003107
Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer
Completed·—·Phase 2·NCT00003335·44 enrolled
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Completed·CCalifornia Cancer Consortium·Phase 1·NCT00104923·29 enrolled
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
Completed·UUniversity of California, San Francisco·Phase 1·NCT00301951·7 enrolled
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 1·NCT00389428·48 enrolled
XK469R in Treating Patients With Refractory Hematologic Cancer
Completed·National Cancer Institute (NCI)·Phase 1·NCT00095797·60 enrolled
Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer
Completed·VVirginia Commonwealth University·Phase 1·NCT00064285·22 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)